Wuxi Griffin has recently completed construction of their 2,550 m² filling facility in Wuxi, China. It is a Swedish and a Chinese company that have joined forces in this new project. The new contract manufacturer Wuxi Griffin will focus on providing aseptic filling services globally to western GMP standards.

Products to be manufactured in the new facility include MAbs, vaccine, recombinant proteins as well as biosimilars and small molecule drugs (traditional). RABS and Isolator production technology is in place for manufacturing. There is flexibility for clinical trial manufacturing (small and medium sized batches) as well as commercial manufacturing.

The China Opportunity
China is currently the second largest pharmaceutical market and the fastest growing in the world. Western companies wanting to expand need to establish presence in China.

“There are few domestic Chinese contract manufacturers that are international players. There is a gap between the Chinese manufacturers capabilities and the regulatory requirements from the West. Wuxi Griffin is filling this gap by offering Western GMP compliance from China”, says Torgny Lundgren, CEO of Wuxi Griffin Pharmaceutical Co. Ltd.

“We meet the needs of our Chinese customers wanting western quality pharmaceuticals but also assist western pharmaceutical companies to a fast-track release of their products to the Chinese market”, mentioned by Lundgren.